Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer
BackgroundIncreasing evidence has revealed an important role of versican (VCAN) on various aspects of cancer progression. Here, we assessed the impact of VCAN expression on prognosis and the response to adjuvant therapy and immunotherapy in patients with gastric cancer (GC).MethodsFour independent c...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.960570/full |
| _version_ | 1797995413386559488 |
|---|---|
| author | Junquan Song Junquan Song Rongyuan Wei Rongyuan Wei Shiying Huo Shiying Huo Chenchen Liu Chenchen Liu Xiaowen Liu Xiaowen Liu |
| author_facet | Junquan Song Junquan Song Rongyuan Wei Rongyuan Wei Shiying Huo Shiying Huo Chenchen Liu Chenchen Liu Xiaowen Liu Xiaowen Liu |
| author_sort | Junquan Song |
| collection | DOAJ |
| description | BackgroundIncreasing evidence has revealed an important role of versican (VCAN) on various aspects of cancer progression. Here, we assessed the impact of VCAN expression on prognosis and the response to adjuvant therapy and immunotherapy in patients with gastric cancer (GC).MethodsFour independent cohorts containing 1353 patients with GC, were utilized to investigate the effect of VCAN expression on prognosis and response to adjuvant therapy in GC. Two cohorts treated with immune checkpoint blockades were included to assess the predict value of VCAN expression on response to immunotherapy. Moreover, the bulk RNA-seq and single-cell RNA-seq data were analyzed to illustrate the role of VCAN in tumor microenvironment. Clinical outcomes of patient subgroups were compared by Kaplan-Meier curves with the log-rank test.ResultHigh VCAN expression was associated with poor prognosis for patients with GC. Compared with patients with high VCAN expression, patients with low VCAN expression benefited more from adjuvant chemotherapy and adjuvant chemoradiotherapy. Moreover, patients with high VCAN expression tended to be resistant to immunotherapy, and VCAN could serve as a promising indicator for predicting the response to immunotherapy. VCANhigh tumors showed a specific microenvironment with more cancer associated fibroblasts infiltration and significant enrichment of stromal relevant signaling pathways.ConclusionVCAN could predict the response to adjuvant chemotherapy, adjuvant chemoradiotherapy and immunotherapy in GC, and designing new medicine target to VCAN might be an effective way to improve the efficacy of several treatment options for GC. |
| first_indexed | 2024-04-11T10:01:13Z |
| format | Article |
| id | doaj.art-efa421a2f8bb4a95a152d2d71546f37b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T10:01:13Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-efa421a2f8bb4a95a152d2d71546f37b2022-12-22T04:30:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.960570960570Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancerJunquan Song0Junquan Song1Rongyuan Wei2Rongyuan Wei3Shiying Huo4Shiying Huo5Chenchen Liu6Chenchen Liu7Xiaowen Liu8Xiaowen Liu9Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, ChinaDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, ChinaDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, ChinaDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, ChinaDepartment of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College of Fudan University, Shanghai, ChinaBackgroundIncreasing evidence has revealed an important role of versican (VCAN) on various aspects of cancer progression. Here, we assessed the impact of VCAN expression on prognosis and the response to adjuvant therapy and immunotherapy in patients with gastric cancer (GC).MethodsFour independent cohorts containing 1353 patients with GC, were utilized to investigate the effect of VCAN expression on prognosis and response to adjuvant therapy in GC. Two cohorts treated with immune checkpoint blockades were included to assess the predict value of VCAN expression on response to immunotherapy. Moreover, the bulk RNA-seq and single-cell RNA-seq data were analyzed to illustrate the role of VCAN in tumor microenvironment. Clinical outcomes of patient subgroups were compared by Kaplan-Meier curves with the log-rank test.ResultHigh VCAN expression was associated with poor prognosis for patients with GC. Compared with patients with high VCAN expression, patients with low VCAN expression benefited more from adjuvant chemotherapy and adjuvant chemoradiotherapy. Moreover, patients with high VCAN expression tended to be resistant to immunotherapy, and VCAN could serve as a promising indicator for predicting the response to immunotherapy. VCANhigh tumors showed a specific microenvironment with more cancer associated fibroblasts infiltration and significant enrichment of stromal relevant signaling pathways.ConclusionVCAN could predict the response to adjuvant chemotherapy, adjuvant chemoradiotherapy and immunotherapy in GC, and designing new medicine target to VCAN might be an effective way to improve the efficacy of several treatment options for GC.https://www.frontiersin.org/articles/10.3389/fimmu.2022.960570/fullVCANgastric cancercancer associated fibroblastsadjuvant chemotherapyimmunotherapy |
| spellingShingle | Junquan Song Junquan Song Rongyuan Wei Rongyuan Wei Shiying Huo Shiying Huo Chenchen Liu Chenchen Liu Xiaowen Liu Xiaowen Liu Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer Frontiers in Immunology VCAN gastric cancer cancer associated fibroblasts adjuvant chemotherapy immunotherapy |
| title | Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| title_full | Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| title_fullStr | Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| title_full_unstemmed | Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| title_short | Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| title_sort | versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer |
| topic | VCAN gastric cancer cancer associated fibroblasts adjuvant chemotherapy immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.960570/full |
| work_keys_str_mv | AT junquansong versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT junquansong versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT rongyuanwei versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT rongyuanwei versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT shiyinghuo versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT shiyinghuo versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT chenchenliu versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT chenchenliu versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT xiaowenliu versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer AT xiaowenliu versicanenrichmentpredictspoorprognosisandresponsetoadjuvanttherapyandimmunotherapyingastriccancer |